Literature DB >> 30575409

Evolving role of human papillomavirus as a clinically significant biomarker in head and neck squamous cell carcinoma.

Caitlin McMullen1, Christine H Chung1, Juan C Hernandez-Prera2.   

Abstract

Introduction: The majority of squamous cell carcinoma (SCC) of the oropharynx, one of the sites within the head and neck region, is now associated with high-risk human papillomavirus (HPV) in North America. Several modalities are available to determine the HPV status, however, the understanding of each assay in its application and limitations is essential for accurate interpretation and appropriate utilization of results in management of these patients. Areas covered: This expert review will cover the role of HPV in head and neck squamous cell carcinoma (HNSCC), indications for HPV testing, HPV detection methods in tumors, saliva and serum, and exploiting HPV status as a prognostic biomarker of clinical outcome in HNSCC. Expert commentary: The HPV status is the most significant diagnostic and prognostic biomarker in HNSCC, specifically in the oropharynx. Research underway is currently delineating the role of HPV and p16 testing in non-oropharyngeal sites. While the feasibility of non-invasive serum and saliva testing for HPV detection has been established, the clinical application of these assays is still evolving.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; biomarker; human papillomavirus

Mesh:

Substances:

Year:  2018        PMID: 30575409     DOI: 10.1080/14737159.2019.1559056

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  5 in total

1.  Phase II Multi-institutional Clinical Trial Result of Concurrent Cetuximab and Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

Authors:  Nabil F Saba; Marcelo Bonomi; Christine H Chung; Jiannong Li; Conor E Steuer; Priyanka Bhateja; Matthew Johnson; Jude Masannat; Maria I Poole; Feifei Song; Juan C Hernandez-Prera; Helen Molina; Bruce M Wenig; Sunil Kumar; Charlotte Kuperwasser; Philip J Stephens; Joaquim M Farinhas; Dong M Shin; Julie A Kish; Jameel Muzaffar; Kedar Kirtane; James W Rocco; Michael J Schell
Journal:  Clin Cancer Res       Date:  2022-06-01       Impact factor: 13.801

Review 2.  Recent Advances and Future Directions in Clinical Management of Head and Neck Squamous Cell Carcinoma.

Authors:  Jameel Muzaffar; Shahla Bari; Kedar Kirtane; Christine H Chung
Journal:  Cancers (Basel)       Date:  2021-01-18       Impact factor: 6.639

Review 3.  Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck.

Authors:  Razvan Iacob; Matei Mandea; Speranta Iacob; Catalina Pietrosanu; Doru Paul; Razvan Hainarosie; Cristian Gheorghe
Journal:  Front Med (Lausanne)       Date:  2022-04-29

4.  Concordance of p16INK4a and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International Study.

Authors:  Marisa Mena; Xin Wang; Sara Tous; Beatriz Quiros; Omar Clavero; Maria Alejo; Francisca Morey; Miren Taberna; Xavier Leon Vintro; Belén Lloveras Rubio; Llúcia Alos; Hisham Mehanna; Wim Quint; Michael Pawlita; Massimo Tommasino; Miguel Angel Pavón; Nubia Muñoz; Silvia De Sanjose; Francesc Xavier Bosch; Laia Alemany
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

5.  Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Karl Payne; Matthew Pugh; Jill Brooks; Nikolaos Batis; Graham Taylor; Paul Nankivell; Hisham Mehanna
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.